Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial

  • Gavilá, J.
  • Oliveira, M.
  • Pascual, T.
  • Perez-Garcia, J.
  • Gonzàlez, X.
  • Canes, J.
  • Paré, L.
  • Calvo, I.
  • Ciruelos, E.
  • Muñoz, M.
  • Virizuela, J.A.
  • Ruiz, I.
  • Andrés, R.
  • Perelló, A.
  • Martínez, J.
  • Morales, S.
  • Marín-Aguilera, M.
  • Martínez, D.
  • Quero, J.C.
  • Llombart-Cussac, A.
  • Prat, A.
Background: The Opti-HER HEART trial aimed to optimize activity while minimizing cardiac risk by combiningtrastuzumab, pertuzumab, and paclitaxel with non-pegylated liposomal doxorubicin in the treatment of HER2-positive early breast cancer. Methods: Patients with stage II–IIIB HER2-positive breast cancer received neoadjuvant trastuzumab, pertuzumab, paclitaxel, and a non-pegylated liposomal doxorubicinevery three weeks for six cycles. The primary endpoint wascardiac safety during neoadjuvant therapy. Type A (symptomatic congestive heart failure) and B (asymptomaticreduction of left ventricular ejection fraction) cardiacevents were evaluated. Secondary endpoints included theevaluation of the pathological complete response (pCR) rate and overall response rate, among others. As anad-hoc exploratory analysis, the expression of 55 breast cancer-related genes, including thePAM50genes, wasmeasured in 58 baseline tumor samples and 60 surgical specimens. Results: Eighty-three patients were recruited. The incidence of cardiac events during neoadjuvant treatment was 2.4%.No type A cardiac event was observed. The overall pCR rate was 56.6% (95% confidence interval (CI) 45.3–67.5%).The HER2-enriched subtype, which represented 52.0% ofall baseline samples, was associated with a higher pCRrate compared to non-HER2-enriched tumors (83.3% vs. 46.3%; odds ratio 5.76, 95% CI 1.71–19.42). The association ofsubtype with pCR was independent of known clinicopathological variables, including hormone receptor status.Compared to baseline samples, surgical specimens showed a significant downregulation of proliferation-related genes(MKI67andCCNB1)andERBB2levels, and a significant upregulation of luminal-related (ESR1andPGR)andimmune(CD8A)genes. Conclusions: The combination of dual HER2 blockade with trastuzumab and pertuzumab with paclitaxel andnon-pegylated liposomal doxorubicin is associated with a low rate of cardiac events. The HER2-enriched subtype isassociated with a high rate of pCR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

  • Pascual, Tomás
  • Martin, Miguel
  • Fernández-Martínez, Aranzazu
  • Alba, Emilio
  • Rodríguez-Lescure, Álvaro
  • Cortés Castan, Javier
  • Paré, Laia
No luminal; Subtipus intrínsec; Càncer de mama, No luminal; Subtipo intrínseco; Cáncer de mama, Non-luminal; Intrinsic subtype, Breast cancer, Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estrogen receptor (ER), progesterone receptor (PR) and Ki67 tumor cells, was derived in a combined cohort of 5 studies (training dataset) and tested in a combined cohort of 3 studies. The performance of NOLUS was estimated using Area Under the ROC Curve (AUC). Results: In the training dataset (n = 903) and compared to luminal disease, non-luminal disease had lower percentage of ER-positive cells (median 65.2 vs. 86.2%, p < 0.01) and PR-positive cells (33.2 vs. 56.4%, p < 0.01) and higher percentage of Ki67-positive cells (18.2 vs. 13.1%, p = 0.01). A NOLUS formula was derived: −0.45*ER −0.28*PR +0.27*Ki67 + 73.02. The proportion of non-luminal tumors in NOLUS-positive (≥51.38) and NOLUS-negative (<51.38) groups was 52.6 and 8.7%, respectively. In the testing dataset (n = 514), NOLUS was found significantly associated with non-luminal disease (p < 0.01) with an AUC 0.902. The proportion of non-luminal tumors in NOLUS-positive and NOLUS-negative groups was 76.9% (56.4–91.0%) and 2.6% (1.4–4.5%), respectively. The sensitivity and specificity of the pre-specified cutoff was 59.3 and 98.7%, respectively. Conclusions: In the absence of gene expression data, NOLUS can help identify non-luminal disease within HR+/HER2-negative breast cancer., This work was supported by Instituto de Salud Carlos III - PI16/00904 (to AP), Banco Bilbao Vizcaya Argentaria Foundation (to AP), Pas a Pas (to AP), Save the Mama (to AP), Breast Cancer Research Foundation (to AP), Fundación Mutua Madrileña- Investigación en Salud 2018 (to AP), SEOM Translational Research Grant (to AF-M.), Banca d'Italia (to GP), and by T.C.I. telecomunicazioni (to GP).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

  • Griguolo, Gaia
  • Pascual, Tomás
  • Fasani, Roberta
  • Chic, N.
  • Antunes de Melo Oliveira, Ana Mafalda
  • Nuciforo, Paolo Giovanni
  • Serna, Garazi
  • Guardia, Xavier
Taca de plasma sec; Hepatitis C; Targeta de separació de plasma, Mancha de plasma seco; Hepatitis C; Tarjeta de separación de plasma, Dried plasma spot; Hepatitis C; Plasma separation card, Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes in tumour-immune contexture, as assessed by stromal tumour-infiltrating lymphocytes (sTILs) and by multiplexed spatial cellular phenotyping, during treatment with lapatinib-trastuzumab in HER2+ BC patients (PAMELA trial). Moreover, we evaluate the relationship of tumour-immune contexture with hormone receptor status, intrinsic subtype and immune-related gene expression. sTIL levels increase after 2 weeks of HER2 blockade in HR-negative disease and HER2-enriched subtype. This is linked to a concomitant increase in cell density of all four immune subpopulations (CD3+, CD4+, CD8+, Foxp3+). Moreover, immune contexture analysis showed that immune cells spatially interacting with tumour cells have the strongest association with response to anti-HER2 treatment. Subsequently, sTILs consistently decrease at the surgery in patients achieving pathologic complete response, whereas most residual tumours at surgery remain inflamed, possibly reflecting a progressive loss of function of T cells. Understanding the features of the resulting tumour immunosuppressive microenvironment has crucial implications for the design of new strategies to de-escalate or escalate systemic therapy in early-stage HER2+ BC., We thank all the patients and family members for participating in the PAMELA study. This study was supported, in part, by Instituto de Salud Carlos III—PI16/00904, The Breast Cancer Research Foundation and Fundación Científica Asociación Española Contra el Cáncer (Ayuda Postdoctoral AECC 2017), Fundación Merck—Immunología and Comprehensive Programme of Cancer Immunotherapy & Immunology (CAIMI) BBVA Foundation (grant number 89/2017). Acknowledgements to the Cellex Foundation for providing research facilities and equipment. G.G. acknowledges funding from a 2019 Conquer Cancer Foundation YIA in Breast Cancer. This work has been realised in the Surgery and Morphological Sciences Doctorate framework of Univ Autonoma de Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  • Schettini, Francesco
  • Chic, Nuria
  • Brasó-Maristany, Fara
  • Pascual, Tomás
  • Peg Camara, Vicente
  • Fasani, Roberta
  • Paré, Laia
  • Conte, Benedetta
Càncer de mama; Genòmica del càncer; Recerca translacional, Cáncer de mama; Genómica del cáncer; Investigación traslacional, Breast cancer; Cancer genomics; Translational research, Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression., This work was supported by the grants from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement No. 847912 (to A.P.), the Instituto de Salud Carlos III-PI16/00904 (to A.P.), Pas a Pas (to A.P.), Save the Mama (to A.P.), Breast Cancer Now-2018NOVPCC1294 (to A.P.), Fundación Científica Asociación Española Contra el Cáncer-Ayuda Postdoctoral AECC 2017 (to F.B.-M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.) and PhD4MD - Departament de Salut expedient SLT008/18/00122 (to N.C.).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer

  • Palafox, Marta|||0000-0002-1762-3250
  • Monserrat, Laia|||0000-0002-8802-3033
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ibrahimi, Nusaibah|||0000-0003-4537-0323
  • Kannan, Srinivasaraghavan|||0000-0002-9539-5249
  • Mina, Leonardo
  • Herrera-Abreu, Maria Teresa
  • Òdena, Andreu|||0000-0003-1529-880X
  • Sánchez Guixé, Mònica|||0000-0002-9430-4413
  • Capelán, Marta
  • Azaro, Analía
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Grueso, Judit|||0000-0003-1093-7940
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Su, Faye
  • Lin, Kui
  • Clarke, Robert B.|||0000-0001-5407-3123
  • Caldas, Carlos|||0000-0003-3547-1489
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Michiels, Stefan|||0000-0002-6963-2968
  • García-Sanz, Alicia
  • Turner, Nicholas C.|||0000-0001-8937-0873
  • Prat, Aleix|||0000-0003-2377-540X
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Verma, Chandra S.
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Arnedos, Monica
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Serra, Violeta|||0000-0001-6620-1065
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

  • Griguolo, Gaia
  • Pascual, Tomás
  • Fasani, Roberta
  • Chic, N.
  • Antunes de Melo Oliveira, Ana Mafalda
  • Nuciforo, Paolo Giovanni
  • Serna, Garazi
  • Guardia, Xavier
Taca de plasma sec; Hepatitis C; Targeta de separació de plasma, Mancha de plasma seco; Hepatitis C; Tarjeta de separación de plasma, Dried plasma spot; Hepatitis C; Plasma separation card, Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes in tumour-immune contexture, as assessed by stromal tumour-infiltrating lymphocytes (sTILs) and by multiplexed spatial cellular phenotyping, during treatment with lapatinib-trastuzumab in HER2+ BC patients (PAMELA trial). Moreover, we evaluate the relationship of tumour-immune contexture with hormone receptor status, intrinsic subtype and immune-related gene expression. sTIL levels increase after 2 weeks of HER2 blockade in HR-negative disease and HER2-enriched subtype. This is linked to a concomitant increase in cell density of all four immune subpopulations (CD3+, CD4+, CD8+, Foxp3+). Moreover, immune contexture analysis showed that immune cells spatially interacting with tumour cells have the strongest association with response to anti-HER2 treatment. Subsequently, sTILs consistently decrease at the surgery in patients achieving pathologic complete response, whereas most residual tumours at surgery remain inflamed, possibly reflecting a progressive loss of function of T cells. Understanding the features of the resulting tumour immunosuppressive microenvironment has crucial implications for the design of new strategies to de-escalate or escalate systemic therapy in early-stage HER2+ BC., We thank all the patients and family members for participating in the PAMELA study. This study was supported, in part, by Instituto de Salud Carlos III—PI16/00904, The Breast Cancer Research Foundation and Fundación Científica Asociación Española Contra el Cáncer (Ayuda Postdoctoral AECC 2017), Fundación Merck—Immunología and Comprehensive Programme of Cancer Immunotherapy & Immunology (CAIMI) BBVA Foundation (grant number 89/2017). Acknowledgements to the Cellex Foundation for providing research facilities and equipment. G.G. acknowledges funding from a 2019 Conquer Cancer Foundation YIA in Breast Cancer. This work has been realised in the Surgery and Morphological Sciences Doctorate framework of Univ Autonoma de Barcelona.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  • Schettini, Francesco
  • Chic, Nuria
  • Brasó-Maristany, Fara
  • Pascual, Tomás
  • Peg Camara, Vicente
  • Fasani, Roberta
  • Paré, Laia
  • Conte, Benedetta
Càncer de mama; Genòmica del càncer; Recerca translacional, Cáncer de mama; Genómica del cáncer; Investigación traslacional, Breast cancer; Cancer genomics; Translational research, Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression., This work was supported by the grants from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement No. 847912 (to A.P.), the Instituto de Salud Carlos III-PI16/00904 (to A.P.), Pas a Pas (to A.P.), Save the Mama (to A.P.), Breast Cancer Now-2018NOVPCC1294 (to A.P.), Fundación Científica Asociación Española Contra el Cáncer-Ayuda Postdoctoral AECC 2017 (to F.B.-M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.) and PhD4MD - Departament de Salut expedient SLT008/18/00122 (to N.C.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

  • Pascual, Tomás
  • Martin, Miguel
  • Fernández-Martínez, Aranzazu
  • Alba, Emilio
  • Rodríguez-Lescure, Álvaro
  • Cortés Castan, Javier
  • Paré, Laia
No luminal; Subtipus intrínsec; Càncer de mama, No luminal; Subtipo intrínseco; Cáncer de mama, Non-luminal; Intrinsic subtype, Breast cancer, Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estrogen receptor (ER), progesterone receptor (PR) and Ki67 tumor cells, was derived in a combined cohort of 5 studies (training dataset) and tested in a combined cohort of 3 studies. The performance of NOLUS was estimated using Area Under the ROC Curve (AUC). Results: In the training dataset (n = 903) and compared to luminal disease, non-luminal disease had lower percentage of ER-positive cells (median 65.2 vs. 86.2%, p < 0.01) and PR-positive cells (33.2 vs. 56.4%, p < 0.01) and higher percentage of Ki67-positive cells (18.2 vs. 13.1%, p = 0.01). A NOLUS formula was derived: −0.45*ER −0.28*PR +0.27*Ki67 + 73.02. The proportion of non-luminal tumors in NOLUS-positive (≥51.38) and NOLUS-negative (<51.38) groups was 52.6 and 8.7%, respectively. In the testing dataset (n = 514), NOLUS was found significantly associated with non-luminal disease (p < 0.01) with an AUC 0.902. The proportion of non-luminal tumors in NOLUS-positive and NOLUS-negative groups was 76.9% (56.4–91.0%) and 2.6% (1.4–4.5%), respectively. The sensitivity and specificity of the pre-specified cutoff was 59.3 and 98.7%, respectively. Conclusions: In the absence of gene expression data, NOLUS can help identify non-luminal disease within HR+/HER2-negative breast cancer., This work was supported by Instituto de Salud Carlos III - PI16/00904 (to AP), Banco Bilbao Vizcaya Argentaria Foundation (to AP), Pas a Pas (to AP), Save the Mama (to AP), Breast Cancer Research Foundation (to AP), Fundación Mutua Madrileña- Investigación en Salud 2018 (to AP), SEOM Translational Research Grant (to AF-M.), Banca d'Italia (to GP), and by T.C.I. telecomunicazioni (to GP).